We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Circio Holding Asa | LSE:0RIS | London | Ordinary Share | NO0013033795 | CIRCIO HOLDING ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.98 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Home Health Care Services | 10M | -432.9M | -2.2969 | -6.96 | 3.01B |
OSLO, Norway, Nov. 4, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2021 results. Targovax's CEO will give an online presentation and update on the clinical program to investors, analysts and the press at 10:00 CET today (details below).
THIRD QUARTER HIGHLIGHTS
POST-PERIOD HIGHLIGHTS
KEY FIGURES
Amounts in NOK thousands | 3Q 2021 | 3Q 2020 | 9M 2021 | 9M 2020 | FY 2020 |
Total operating revenues | - | 34 | - | 624 | 624 |
Total operating expenses | -22 539 | -22 073 | -70 078 | -81 652 | -104 524 |
Operating profit/loss | -22 539 | -22 039 | -70 078 | -81 028 | -103 901 |
Net financial items | -781 | -718 | -1 294 | -1 089 | -4 503 |
Income tax | 11 | 73 | 42 | 220 | 277 |
Net profit/loss | -23 309 | -22 684 | -71 330 | -81 898 | -108 126 |
Basic and diluted EPS (NOK/share) | -0.27 | -0.30 | -0.82 | -1.10 | -1.40 |
Net change in cash | -17 127 | -23 808 | -68 257 | 7 228 | 51 893 |
Cash and cash equivalents start of period | 71 192 | 101 465 | 122 321 | 70 429 | 70 429 |
Cash and cash equivalents end of period | 54 064 | 77 657 | 54 064 | 77 657 | 122 321 |
Erik Digman Wiklund, CEO commented: "Taking over the leadership of Targovax at a time when we have demonstrated a clear signal of efficacy accompanied by a deep biomarker data package for our lead candidate ONCOS-102, is a truly exciting opportunity. The insights we have gained allow us to select the optimal combination strategy for the next development step, as well as to design innovative and differentiated second generation ONCOS vectors to shape our platform for the future."
Presentation
We invite to a live webcast today at 10.00 CET. You can join the webcast here. It will be possible to ask questions during the presentation.
Reporting material
TRVX Q3 report.pdf
TRVX Q3 presentation.pdf
The quarterly report and presentation are also available at the website www.targovax.com.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa--third-quarter-2021-results,c3446803
The following files are available for download:
https://mb.cision.com/Public/17093/3446803/afeb113e438d4cce.pdf | TRVX Q3 report |
https://mb.cision.com/Public/17093/3446803/a025da7d0e3836c3.pdf | TRVX 3Q presentation |
Copyright 2021 PR Newswire
1 Year Circio Holding Asa Chart |
1 Month Circio Holding Asa Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions